Sara M. Tolaney, MD, MPH, discusses new data from the ASCENT-04 trial and their implications for community oncologists.

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

CHICAGO — First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy plus pembrolizumab among patients with metastatic triple ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Sacituzumab govitecan links an anti-Trop-2 antibody to SN-38, one of the chemotherapy drugs used to kill cancer cells in triple-negative breast cancer [3].

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors (treatments ...

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive locally advanced or metastatic triple-negative breast cancer.

WEDNESDAY, Aug. 14, 2024 (HealthDay News) -- For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug ...

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC News provided by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC. PR Newswire. CHENGDU, China, Nov. 27, 2024.

Gilead is continuing to explore sacituzumab govitecan in other phase 3 trials, including ASCENT-07 (ClinicalTrials.gov Identifier: NCT05840211) for hormone receptor–positive, human epidermal ...